As a key part of our business strategy to disseminate the Organoid Technology, HUB offers licenses to its proprietary Organoid Technology, know-how and access to HUB biobanks. The licenses allow industry to use the technology themselves. HUB offers the licenses including tech transfer training to help establish the technology in house. As a drug discovery platform, HUB Organoids can be exploited for target discovery and genomic and functional studies at a scale that cannot be achieved by clinically relevant models. In drug development, HUB Organoids provide drug efficacy, safety, and mechanistical data. Furthermore, disease specific collections of Organoids enable pre-clinical stratification of patient populations.
HUB has created Organoid biobanks from patient material that capture disease heterogeneity in diseases such as Cancer, Cystic Fibrosis, COPD and IBD. The biobanks are an expanding resource of highly characterized Organoids for different organ systems and include both genetic and clinical data of the patient.
As a key part of our business strategy, HUB offers licenses to its proprietary Organoid Technology, know-how and access to HUB biobanks.
Leveraging our expertise in field of Organoid Technology, HUB offers research collaborations based on its state-of-the-art technology platform and extensive experience with innovative technologies. HUB has many collaborations with its partners to develop new organoid models, novel assays, perform mechanism of action studies and generate (propriety) biobanks in range of different disease areas.
HUB aims to drive innovation through spin out opportunities as stand alone or in combination with other innovative technologies through a variety of commercial structures.